This Podcast Will Kill You

Ep 203 Cancer Part 2: Why does it happen?

March 10, 2026

Key Takeaways Copied to clipboard!

  • Cancer is fundamentally a consequence of complex multicellular life, arising when cells break the evolutionary 'multicellularity playbook' by exploiting cooperative mechanisms for uncontrolled growth. 
  • Cancer development is not solely a genetic disease but a result of gene-by-environment (G by E) interactions, requiring the right set of mutations in the right environment to take hold. 
  • The observation that larger, longer-lived species do not necessarily have higher cancer rates than smaller, shorter-lived ones is known as Peto's Paradox, suggesting that cancer suppression mechanisms evolve alongside the risks of multicellularity. 
  • The expected correlation between larger body size/longer lifespan and higher cancer rates across species is contradicted by the observation known as Píto's Paradox, where large, long-lived animals like elephants often have lower cancer risks than smaller, shorter-lived ones like mice. 
  • Within a species, cancer risk generally correlates with size and age (e.g., bigger dogs get more cancer than smaller dogs), suggesting species-level differences are due to protective mechanisms like having more tumor suppressor genes (e.g., elephants having 20 copies of TP53 compared to human's two). 
  • Applying evolutionary principles to treatment, approaches like adaptive therapy, modeled after integrated pest management, aim to control cancer by using lower, adjusted drug doses to select for slower-growing cells and delay the emergence of drug resistance, rather than attempting immediate eradication. 

Segments

Listener Stories Introduction
Copied to clipboard!
(00:00:01)
  • Key Takeaway: Listeners shared personal, vulnerable accounts of cancer diagnoses, including colon cancer with Lynch syndrome, metastatic breast cancer, skin lymphoma, and glioblastoma.
  • Summary: Multiple listeners shared detailed personal journeys involving cancer diagnoses, highlighting the emotional toll, specific genetic markers like Lynch syndrome and BRCA1, and the impact on their lives and bodies. These firsthand accounts serve as the backbone for understanding the human experience of cancer, contrasting with the episode’s biological focus. The stories underscore that cancer experiences are highly individualized.
Defining Cancer and Cell Rules
Copied to clipboard!
(00:19:12)
  • Key Takeaway: Cancer is defined as uncontrolled cell growth and spread, which fundamentally involves cells discarding the instruction manual for multicellular cooperation.
  • Summary: The National Cancer Institute definition of cancer is reiterated: a disease where cells grow uncontrollably and spread. Normal cell division is tightly regulated by DNA instructions, similar to following a Lego kit manual. Cancer cells ignore these instructions, effectively throwing out the manual and breaking rules like responding to growth factors or initiating programmed cell death (apoptosis).
Oncogenes and Tumor Suppressors
Copied to clipboard!
(00:24:00)
  • Key Takeaway: Cancer cells activate oncogenes (like RAS) to continuously signal growth and disable tumor suppressor genes (like BRCA1 and TP53) that normally halt the cell cycle or initiate apoptosis.
  • Summary: Mutations in oncogenes act as a stuck gas pedal, allowing continuous cell division, and are present in almost all cancers. Tumor suppressor genes, such as BRCA1 (involved in DNA repair) and TP53 (the ‘guardian of the genome’), are often inactivated, removing the cell’s brakes. Inactivation of TP53 function is seen in over 90% of cancers, highlighting its critical role in maintaining genomic integrity.
Cancer’s Evolving Traits
Copied to clipboard!
(00:28:52)
  • Key Takeaway: Cancer cells acquire traits like indefinite replication, altered metabolism for survival in low-oxygen areas, and the ability to induce angiogenesis (new blood vessel formation).
  • Summary: Cancer cells upregulate mechanisms to live forever, overriding the natural limit on cell divisions. They also alter their metabolism to thrive in nutrient-poor or low-oxygen tumor microenvironments. Furthermore, tumors actively promote angiogenesis to create their own blood supply to feed the growing mass.
Genetics vs. Environment
Copied to clipboard!
(00:32:36)
  • Key Takeaway: Cancer is not purely a genetic disease but a disease of genetic and environmental interactions, where mutations are necessary but not sufficient for cancer formation.
  • Summary: The presence of cancer-associated mutations alone does not guarantee cancer development, emphasizing that environmental factors are crucial. Exposures like tobacco smoke or viruses can cause DNA damage, but the environment also influences the tumor microenvironment, affecting immune evasion and nutrient access. Cancer requires a ‘perfect storm’ of genetic changes and environmental support to take hold.
Evolutionary Framework of Cancer
Copied to clipboard!
(00:42:21)
  • Key Takeaway: Viewing cancer through an evolutionary lens reframes it as cells acting as parasites that have evolved traits beneficial for their own proliferation, rather than an external enemy.
  • Summary: The evolutionary perspective suggests cancer cells are simply following evolutionary drivers, leveraging traits that allow them to proliferate and spread within the host organism. Cancer is not a one-time event but an evolving, dynamic mass of genetically diverse cells, which explains why resistance to treatment often emerges. The hosts’ multicellularity playbook requires a balance between chaotic growth and stagnation, meaning cancer risk is not optimally zero.
Cancer Defense Mechanisms
Copied to clipboard!
(00:52:44)
  • Key Takeaway: The body employs intrinsic cellular monitoring, neighborhood cell surveillance, and the global immune system to suppress cancerous growth, reflecting evolutionary trade-offs.
  • Summary: Intrinsic defenses involve internal cell mechanisms, like the TP53 protein, that monitor for DNA errors and initiate repair or self-destruction. Neighborhood surveillance relies on cells requiring constant positive reinforcement from neighbors to continue functioning cooperatively. The immune system acts as a global defense, scrutinizing cells for tumor antigens that signal inappropriate behavior, similar to how it targets viruses.
Peto’s Paradox Explained
Copied to clipboard!
(01:01:16)
  • Key Takeaway: Peto’s Paradox describes the lack of correlation between body size or lifespan and cancer risk across species, as larger animals like elephants have evolved superior cancer suppression mechanisms.
  • Summary: If cancer risk correlated only with cell count or lifespan, large, long-lived animals like elephants should have far higher cancer rates than humans, but they do not; in fact, elephants have lower rates. Conversely, mice often show higher cancer rates than humans, defying simple size/longevity predictions. This paradox indicates that species have evolved varying degrees of cancer suppression mechanisms to manage the inherent risks of multicellularity.
Píto’s Paradox Explained
Copied to clipboard!
(01:01:47)
  • Key Takeaway: Large-bodied and long-lived species do not exhibit higher cancer rates than expected, a phenomenon termed Píto’s Paradox.
  • Summary: It was initially expected that species like elephants and blue whales should have higher cancer rates due to more cells or longer mutation accumulation time, but this is not observed. In fact, elephants are less likely to develop cancer than humans, and mice are more likely to develop cancer than humans. Within a species, however, the expected pattern holds: bigger dogs are more likely to develop cancer than smaller dogs.
Hypotheses for Paradox Resolution
Copied to clipboard!
(01:03:31)
  • Key Takeaway: Protective mechanisms in large species may include having more tumor suppressor genes, lower overall mutation rates, or immune systems better tuned to eliminate precancerous cells.
  • Summary: Elephants possess 20 copies of the TP53 tumor suppressor gene compared to two copies in humans, offering enhanced cellular control. Life history trade-offs might also play a role, where species maturing quickly (like mice) prioritize proliferation even with higher cancer risk, while slower-maturing species invest more in cellular watchfulness.
Other Cross-Species Cancer Patterns
Copied to clipboard!
(01:05:48)
  • Key Takeaway: Birds and reptiles generally have less cancer than placental mammals, and species undergoing genetic bottlenecks show increased cancer rates, suggesting genetic diversity is protective.
  • Summary: Carnivora mammals tend to have higher cancer risks, possibly due to biomagnification of carcinogens, low-fiber diets, or pathogens in raw meat. Deer with rapidly proliferating antlers also show higher rates, linking rapid cell proliferation to increased risk. Low genetic diversity, such as after a bottleneck (like in Santa Catalina Island foxes), significantly increases cancer prevalence.
Evolutionary Mismatch and Treatment Need
Copied to clipboard!
(01:08:00)
  • Key Takeaway: The 40% lifetime cancer risk in humans likely reflects an evolutionary mismatch where modern factors like sedentary lifestyles and longevity increase risk beyond the baseline set by multicellularity.
  • Summary: While cancer risk is never zero from an evolutionary standpoint due to the necessity of proliferation and differentiation, modern environmental factors like smoking, processed foods, and increased lifespan elevate this risk. This necessitates developing new treatment approaches that work with evolution rather than directly attacking cancer.
Adaptive Therapy Strategy
Copied to clipboard!
(01:09:15)
  • Key Takeaway: Adaptive therapy, inspired by integrated pest management, seeks long-term control over eradication by using monitored, adjusted drug doses to keep cancer cells sensitive to treatment.
  • Summary: This approach avoids the evolutionary pressure that leads to resistance by not applying a massive, sustained onslaught of therapy. Resistance mechanisms are costly to maintain, so relaxing treatment pressure allows sensitive cells to outcompete resistant ones, potentially slowing progression and reducing side effects, as shown in prostate cancer trials.
Decoy Drugs and Tumor Maintenance
Copied to clipboard!
(01:14:34)
  • Key Takeaway: Decoy drugs exploit resistance pumps in cancer cells by forcing them to expend energy pumping out harmless molecules, exhausting the cells and potentially preventing metastasis.
  • Summary: For treatment-resistant cancers that use pumps to expel chemotherapy, decoy drugs appear toxic, forcing continuous pumping activity that depletes cellular resources and energy needed for replication. Another concept involves maintaining a tumor at a stable size, rather than shrinking it aggressively, to prevent the hostile environment that might trigger invasion and spread.